Group
RET targeting TKI
The data below refer to patients treated with RET targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Pralsetinib
No data
Selpercatinib
No data